We report a 33-year-old HIV type-1 (HIV-1)-infected male from Sierra Leone who harboured extensive drug resistance mutations to all nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs, including the multi-NRTI-resistance Q151M complex, K65R, M184I and Y181I, after using standard first-line generic fixed-dose stavudine, lamivudine and nevirapine (Triomune™) for 36 months. In the context of non-B subtypes in resource-limited countries, first-line stavudine-containing regimens have been associated with more extensive and complex mutation patterns, compared with subtype B viruses. Whether the extensive and complex NRTI resistance patterns found among African patients failing first-line antiretroviral therapy is explained by viral genetic diversity or by different patient monitoring strategies remains to be elucidated. Emerging multi-NRTI resistance in sub- Saharan Africa would not only compromise second-line treatment options and the success of anti-retroviral rollout, but could also contribute to the spread of drug- resistant variants worldwide.
References
1.
World Health Organization.Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009. (Updated 4 November 2009. Accessed 1 April 2010.) Available from http://www.who.int/hiv/pub/tuapr_2009_en.pdf.
2.
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups.Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet2006; 367: 817–824.
3.
IversL.C., KendrickD., DoucetteK.Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis2005; 41: 217–224.
4.
JahnA., FloydS., CrampinA.C.Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet2008; 371: 1603–1611.
5.
World Health Organization.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. (Updated 15 July 2010. Accessed 1 August 2010.) Available from http://www.who.int/hiv/pub/arv/adult2010/en/index.html.
6.
GuptaR.K., HillA., SawyerA.W.Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis2009; 9: 409–417.
7.
KantorR., KatzensteinD.A., EfronB.Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med2005; 2: e112.
Cozzi-LepriA., RuizL., LovedayC.Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther2005; 10: 791–802.
10.
FlandreP., DescampsD., JolyV.Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. Antivir Ther2003; 8: 65–72.
11.
TurnerD., BrennerB.G., RoutyJ.P., PetrellaM., WainbergM.A.Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol2004; 27: 31–39.
12.
Van VaerenberghK., Van LaethemK., AlbertJ.Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother2000; 44: 2109–2117.
13.
ParikhU.M., BachelerL., KoontzD., MellorsJ.W.The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol2006; 80: 4971–4977.
14.
GallantJ.E., StaszewskiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA2004; 292: 191–201.
15.
HawkinsC.A., ChaplinB., IdokoJ.Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr2009; 52: 228–234.
16.
HosseinipourM.C., van OosterhoutJ.J., WeigelR.The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS2009; 23: 1127–1134.
17.
OrrellC., WalenskyR.P., LosinaE., PittJ., FreedbergK.A., WoodR.HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther2009; 14: 523–531.
18.
SungkanuparphS., ManosuthiW., KiertiburanakulS., PiyavongB., ChumpathatN., ChantratitaW.Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis2007; 44: 447–452.
19.
WallisC.L., MellorsJ.W., VenterW.D., SanneI., StevensW.Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr2010; 53: 480–484.
20.
InvernizziC.F., CoutsinosD., OliveiraM., MoisiD., BrennerB.G., WainbergM.A.Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis2009; 200: 1202–1206.
21.
HenryM., ThuretI., SolasC., GenotS., ColsonP., TamaletC.Vertical transmission of multidrug-resistant Q151M human immunodeficiency virus type 1 strains. Pediatr Infect Dis J2008; 27: 278–280.
22.
OrrellC., HarlingG., LawnS.D.Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther2007; 12: 83–88.
23.
ArribasJ.R., PulidoF., DelgadoR.Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr2005; 40: 280–287.
24.
DelfraissyJ.F., FlandreP., DelaugerreC.Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS2008; 22: 385–393.
25.
SwindellsS., DiRienzoA.G., WilkinT.Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA2006; 296: 806–814.
